Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona follows an indirect investment in Azeria with a direct one

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into the clinic.

The U.K. investment firm

Read the full 404 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE